MEGHAN CLAIR HUBBARD
Allopathic & Osteopathic Physicians|Family Medicine COATS, NC NPI 1790136620
Browse related groups: Allopathic & Osteopathic Physicians|Family Medicine NC Teva Pharmaceuticals USA, Inc. All categories
General Payments — all program years on this page
$1,262.74
- Category: General Payments
- Program years: PY2019–2024
- Record count: 80
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $259.66 across 9 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $259.66 | 9 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $96.00 | 1 |
| ABBVIE INC. | $46.74 | 3 |
| Novo Nordisk AS | $42.84 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $34.75 | 1 |
| Vanda Pharmaceuticals Inc. | $21.24 | 1 |
| Janssen Biotech, Inc. | $18.09 | 1 |
By program year
Records — PY2024 (9)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1078826032 | Janssen Biotech, Inc. | $18.09 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1086818441 | Novartis Pharmaceuticals Corporation | $34.75 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1096882512 | Novo Nordisk Inc | $26.18 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1097514390 | Novo Nordisk Inc | $16.66 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1103949064 | ABBVIE INC. | $16.20 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1103949066 | ABBVIE INC. | $15.49 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1103949068 | ABBVIE INC. | $15.05 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1133906625 | Vanda Pharmaceuticals Inc. | $21.24 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1151607568 | Teva Pharmaceuticals USA, Inc. | $96.00 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.